• Meenakshi K. Chauhan Delhi Institute of Pharmaceutical Science and Research, Pushp Vihar, Sec-3 New Delhi 110017
  • Shipra Malik Delhi Institute of Pharmaceutical Science and Research, Pushp Vihar, Sec-3 New Delhi 110017



Brazil, China, Europe, infliximab biosimilar, India


A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorized original biological medicinal product (reference medicinal product). A biosimilar demonstrates similarity to the reference biological product in terms of quality characteristics, biological activity, safety and efficacy based on a comprehensive comparability exercise. EMA (European Medicines Agency) was the first to introduce the guidelines for biosimilar approval, effective from June 2006. Biosimilar guideline was released in 2010 in Brazil and 2012 in India. Recently China published its guideline for biosimilar approval in 2015.

This article summarizes the regulatory requirements for approval of biosimilars in India, Europe, Brazil, and China. These countries require comparability exercise of a biosimilar with reference biological product for generating comparative analytical, non-clinical and clinical data (usually one or two phase 1 and phase 3 comparative studies). A case study of infliximab biosimilar approval in India, Brazil and Europe has also been included.


Download data is not yet available.


World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs); 2009. p. 23-30.

Markets, markets. Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Interferons, rHGH), Glycosylated (Monoclonal Antibodies, EPO), Peptides (Glucagon, Calcitonin)) and Application (Oncology, Blood Disorders)-Global Forecast to 2020.; 2015. p. 9-12.

Kandhare AD, Raygude KS, Ghosh P, Gosavi TP, Bodhankar SL. A comparative cross-sectional descriptive study of individual pharmacy Vs mall pharmacies to evaluate customer satisfaction as well as purchasing behavior. Der Pharm Lett 2011;3:71-83.

Calvo B, Zuniga L. The US approach to biosimilars: the long-awaited FDA approval pathway. Biol Drugs 2012;26:357-61.

Kumar R, Sigala S, Malgarini RB, Pimpinella G, Pani L, Pecorelli S, et al. Biosimilars: regulatory status and implications across the World. J Pharmacovigilance 2015;(S3):2.

Berkowitz SA, Engen JR, Mazzeo JR, Jones GB. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat Rev Drug Discovery 2012;11:527-40.

Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D. Clinical considerations for the development of biosimilars in oncology. MAbs 2015;7:286-93.

World Health Organization. Expert committee on biological standardization. Geneva, 19 to 23 October 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. p. 12-8.

Rathore A. Guidelines on similar biologics: regulatory requirements for marketing authorization in India. PDA J Pharm Sci Technol 2011;66:393-3.

Ghosh P, Kandhare AD, Kumar VS, Rajmane AR, Adil M, Bodhankar SL. Determination of clinical outcome and pharmacoeconomics of anti–rheumatoid arthritis therapy using CDAI, EQ–5D–3L and EQ–VAS as indices of disease amelioration. Asian Pac J Trop Dis 2012;2:S671-S678.

Sarkate AP, Murumkar PR, Lokwani DK, Kandhare AD, Bodhankar SL, et al. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity. SAR QSAR Environ Res 2015;26:905-23.

Bhilare NV, Dhaneshwar SS, Sinha AJ, Kandhare AD, Bodhankar SL. Novel thioester prodrug of N-acetylcysteine for odor masking and bioavailability enhancement. Curr Drug Delivery 2016;13:611-20.

Goswami S, Kandhare AD, Zanwar AA, Hegde MV, Bodhankar SL, Shinde S, et al. Oral L-glutamine administration attenuated cutaneous wound healing in Wistar rats. Int Wound J 2016;13:116-24.

Kandhare AD, Alam J, Patil MV, Sinha A, Bodhankar SL. Wound healing potential of naringin ointment formulation via regulating the expression of inflammatory, apoptotic and growth mediators in experimental rats. Pharm Biol 2016;54:419-32.

Kandhare AD, Bodhankar SL, Mohan V, Thakurdesai PA. Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced pulmonary fibrosis in rats: decisive role of Bax, Nrf2, NF-kappaB, Muc5ac, TNF-alpha, and IL-1beta. Chem Biol Interact 2015;237:151-65.

Kandhare AD, Raygude KS, Ghosh P, Gosavi TP, Bodhankar SL. Patentability of animal models: India and the globe. Int J Pharm Biomed Res 2011;2:1024-32.

Ghosh P, Kandhare AD, Gauba D, Raygude KS, Bodhankar SL. Determination of efficacy, adverse drug reactions and cost effectiveness of three triple drug regimens for the treatment of Helicobacter pylori infected acid peptic disease patients. Asian Pac J Trop Dis 2012;2:S783-S789.

Ghosh P, Kandhare AD, Raygude KS, Gauba D, Gosavi TP, Bodhankar SL. Cigarette smoking and H. pylori infection: a meta-analysis of the literature. Der Pharm Lett 2012;4:128-34.

Raygude K, Kandhare A, Ghosh P, Gosavi T, Bodhankar S. Consumption of alcohol and H. pylori infection: A cumulative meta-analysis of the literature. Asian J Biochem Pharm Res 2011;3:338-45.

Visnagri A, Kandhare AD, Chakravarty S, Ghosh P, Bodhankar SL. Hesperidin, a flavanol glycone attenuates experimental diabetic neuropathy via modulation of cellular and biochemical marker to improve nerve functions. Pharm Biol 2014;52:814-28.



How to Cite

Chauhan, M. K., and S. Malik. “REGULATORY GUIDELINES FOR APPROVAL OF BIOSIMILARS IN INDIA, EUROPE, BRAZIL AND CHINA: A COMPREHENSIVE OVERVIEW”. International Journal of Pharmacy and Pharmaceutical Sciences, vol. 8, no. 10, Oct. 2016, pp. 7-11, doi:10.22159/ijpps.2016v8i10.11753.



Review Article(s)